Cadila Pharmaceuticals launches Biscado (Bisoprolol) for cardiovascular disease management in India
Biscado enters India’s beta-blocker therapy space, addressing the growing burden of heart disease with clinically supported…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
CII Telangana to host “Pillars of Protection”conference on pharma and chemical safety
Hyderabad to host industry-wide dialogue on safety, compliance, and risk management in pharma and chemical manufacturing on 25th…
Pharma sector sees $6.96 billion in global deal activity in May 2025, led by GSK, Shionogi, and Eli…
M&A and venture capital deals in the global healthcare sector declined from the 12-month average, with three transactions…
Lupin receives tentative US FDA approval for Oxcarbazepine ER tablets
Oxcarbazepine extended-release tablets to be manufactured at Lupin’s Nagpur facility for US market
Supriya Lifescience’s Saloni Wagh and Shivani Wagh named in 2025 Candere Hurun India Women Leaders…
Leadership of Saloni Wagh and Shivani Wagh recognised as Supriya Lifescience posts highest-ever revenue in FY25
PureTech’s LYT-100 holds potential to expand treatment options for idiopathic pulmonary fibrosis:…
As current IPF treatments face adoption and efficacy challenges, GlobalData highlights LYT-100’s potential to address unmet needs…
ASPA commissions 2nd edition of counterfeiting report ahead of World Anti-Counterfeiting Day
The ASPA–CRISIL 2025 report will assess counterfeiting risks across key sectors in India and offer data-driven insights for brand…
Renewables to account for over half of Brazil’s annual power generation in 2035, forecasts…
Government policies, market liberalisation, and project development expected to accelerate Brazil’s shift from hydropower…
Santosh Mahil appointed CEO of Sekhmet Pharmaventures
Mahil to lead India-based API investment platform backed by PAG, CX Partners, and Samara Capital
Servier India launches IDH1-targeted therapy Ivosidenib for AML and Cholangiocarcinoma
CDSCO approves Servier’s Ivosidenib for treatment of AML and Cholangiocarcinoma patients with IDH1 mutation